Enhabit (NYSE:EHAB) Given New $8.00 Price Target at Bank of America

Enhabit (NYSE:EHAB) had its price target cut by equities research analysts at Bank of America from $9.00 to $8.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “underperform” rating on the stock. Bank of America‘s price objective would indicate a potential downside of 10.31% from the company’s current price.

A number of other analysts have also issued reports on the stock. Jefferies Financial Group lowered shares of Enhabit from a “buy” rating to a “hold” rating and cut their price target for the stock from $14.00 to $8.75 in a research note on Thursday, May 9th. UBS Group raised Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 price objective for the company in a research report on Thursday, March 7th. SVB Leerink raised Enhabit from an “underperform” rating to a “market perform” rating and set a $8.50 price objective for the company in a research report on Tuesday, May 14th. Oppenheimer reissued a “market perform” rating on shares of Enhabit in a research report on Thursday, March 7th. Finally, Leerink Partnrs raised Enhabit from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.79.

Enhabit Stock Up 4.1 %

Shares of NYSE:EHAB opened at $8.92 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.50 and a quick ratio of 1.50. The firm has a market capitalization of $447.39 million, a PE ratio of -5.37, a price-to-earnings-growth ratio of 1.36 and a beta of 1.88. The firm’s 50-day moving average is $9.19 and its two-hundred day moving average is $9.88. Enhabit has a 1 year low of $7.12 and a 1 year high of $14.59.

Enhabit (NYSE:EHAB) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. The company had revenue of $262.40 million for the quarter, compared to analyst estimates of $268.25 million. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. Analysts predict that Enhabit will post 0.24 EPS for the current year.

Insider Activity at Enhabit

In other Enhabit news, Director Jeffrey Bolton purchased 10,000 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was purchased at an average cost of $8.24 per share, with a total value of $82,400.00. Following the completion of the acquisition, the director now directly owns 42,299 shares of the company’s stock, valued at approximately $348,543.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 22,000 shares of company stock valued at $183,700 over the last three months. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enhabit

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new stake in Enhabit in the first quarter valued at approximately $44,000. Gladius Capital Management LP purchased a new stake in Enhabit in the fourth quarter valued at approximately $42,000. ProShare Advisors LLC purchased a new stake in Enhabit in the first quarter valued at approximately $118,000. Family Firm Inc. purchased a new stake in Enhabit in the first quarter valued at approximately $124,000. Finally, Covestor Ltd raised its stake in shares of Enhabit by 1,130.0% during the first quarter. Covestor Ltd now owns 13,456 shares of the company’s stock worth $157,000 after purchasing an additional 12,362 shares during the last quarter.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.